Moderna Raises $2B, AstraZeneca-Amgen & Biokin Score Phase 3 Wins

Moderna's $2 billion offering has made headlines as the mRNA biotech seeks flexibility in its financial dealings. The company will issue convertible senior notes, a move that could give it some much-needed breathing room.

AstraZeneca and Amgen have scored wins with their collaboration on a potential new treatment. The Phase 3 trial results are promising, but more data is needed before any conclusions can be drawn.

In other biotech news, Biokin has also announced successful Phase 3 trials for its own treatment. These developments highlight the ongoing efforts in the field to develop effective treatments and therapies.